Omeros (OMER) Quick Ratio: History & Chart

Omeros Corporation(OMER)

Biotechnology · Seattle, WA

$18.72-0.18 (-0.94%)

Delayed quote: Oct 6, 2026, 12:30 PM EDT

About Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Seattle, WA

175 employees

www.omeros.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gregory A. Demopulos

View full financials

OMER Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

1.94

QUICK RATIO (ACID-TEST) AVG TTM

1.89

QUICK RATIO (ACID-TEST) AVG 3Y

2.51

QUICK RATIO (ACID-TEST) AVG 5Y

2.95

QUICK RATIO (ACID-TEST) AVG 10Y

2.83

QUICK RATIO (ACID-TEST) AVG 15Y

2.55

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

+2.86%

CURRENT VS 3Y AVG

-22.56%

CURRENT VS 5Y AVG

-34.27%

CURRENT VS 10Y AVG

-31.44%

CURRENT VS 15Y AVG

-23.72%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

3.19

median of 761 covered companies

CURRENT VS SECTOR MEDIAN

-39.13%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Omeros Corporation (OMER)	$1.35B	1.94	1.89	2.51	2.95
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.35B	35.85	18.03	18.03	18.03
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	11.09	7.43	12.87	13.91
Inhibrx Biosciences Inc. (INBX)vs ›	$1.40B	5.07	3.94	5.82	6.31
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.41B	11.11	12.01	12.01	12.01
The Pennant Group, Inc. (PNTG)vs ›	$1.42B	1.20	1.17	1.13	1.04
AnaptysBio, Inc. (ANAB)vs ›	$1.43B	5.61	9.29	11.65	16.84
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.44B	1.56	2.29	2.59	3.62
Maze Therapeutics, Inc. (MAZE)vs ›	$1.45B	18.31	12.63	8.12	8.12
Kardigan, Inc. (KARD)vs ›	$1.25B	8.72	9.20	9.20	9.20

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Omeros Corporation (OMER)

$1.35B

1.94

1.89

2.51

2.95

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›

$1.35B

35.85

18.03

Alpha Tau Medical Ltd (DRTS)vs ›

$1.32B

11.09

7.43

12.87

13.91

Inhibrx Biosciences Inc. (INBX)vs ›

$1.40B

5.07

3.94

5.82

6.31

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.41B

11.11

12.01

The Pennant Group, Inc. (PNTG)vs ›

$1.42B

1.20

1.17

1.13

1.04

AnaptysBio, Inc. (ANAB)vs ›

$1.43B

5.61

9.29

11.65

16.84

Ultragenyx Pharmaceutical Inc. (RARE)vs ›

$1.44B

1.56

2.29

2.59

3.62

Maze Therapeutics, Inc. (MAZE)vs ›

$1.45B

18.31

12.63

8.12

Kardigan, Inc. (KARD)vs ›

$1.25B

8.72

9.20

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Omeros Corporation (OMER)?

The quick ratio (acid-test) for OMER stock is 1.94.

Is Omeros Corporation's quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 1.94 is 34% below its 5-year average of 2.95, near the low end of its 5-year range (0.81–7.30).

What is the TTM average quick ratio (acid-test) for Omeros Corporation (OMER)?

The TTM average quick ratio (acid-test) for OMER stock is 1.89.

What is the 3Y average quick ratio (acid-test) for Omeros Corporation (OMER)?

The 3Y average quick ratio (acid-test) for OMER stock is 2.51.

What is the 5Y average quick ratio (acid-test) for Omeros Corporation (OMER)?

The 5Y average quick ratio (acid-test) for OMER stock is 2.95.

What is the 10Y average quick ratio (acid-test) for Omeros Corporation (OMER)?

The 10Y average quick ratio (acid-test) for OMER stock is 2.83.

What is the 15Y average quick ratio (acid-test) for Omeros Corporation (OMER)?

The 15Y average quick ratio (acid-test) for OMER stock is 2.55.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	1.94
2026-03-31	3.03
2025-12-31	2.76
2025-09-30	0.89
2025-06-30	0.81
2025-03-31	1.16
2024-12-31	1.69
2024-09-30	2.96
2024-06-30	3.41
2024-03-31	4.76
2023-12-31	4.09
2023-09-30	2.39
2023-06-30	2.71
2023-03-31	3.00
2022-12-31	3.25
2022-09-30	7.30
2022-06-30	5.01
2022-03-31	6.00
2021-12-31	4.79
2021-09-30	2.12
2021-06-30	2.34
2021-03-31	3.02
2020-12-31	4.08
2020-09-30	4.07
2020-06-30	0.97
2020-03-31	1.46
2019-12-31	1.85
2019-09-30	1.34
2019-06-30	1.59
2019-03-31	1.71
2018-12-31	1.00
2018-09-30	2.68
2018-06-30	3.94
2018-03-31	3.18
2017-12-31	4.10
2017-09-30	4.74
2017-06-30	2.11
2017-03-31	2.97
2016-12-31	3.68
2016-09-30	3.69
2016-06-30	2.01
2016-03-31	1.28
2015-12-31	2.26
2015-09-30	1.75
2015-06-30	2.79
2015-03-31	3.61
2014-12-31	0.47
2014-09-30	1.55
2014-06-30	3.11
2014-03-31	5.16
2013-12-31	1.25
2013-09-30	0.86
2013-06-30	1.95
2013-03-31	1.49
2012-12-31	2.65
2012-09-30	1.44
2012-06-30	0.49
2012-03-31	1.05
2011-12-31	1.37
2011-09-30	2.14
2011-06-30	2.77
2011-03-31	3.01
2010-12-31	2.76
2010-09-30	6.61
2010-06-30	4.25
2010-03-31	5.12
2009-12-31	5.47
2009-09-30	0.41
2009-06-30	0.48
2009-03-31	0.00
2008-12-31	0.87
2008-09-30	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

1.94

2026-03-31

3.03

2025-12-31

2.76

2025-09-30

0.89

2025-06-30

0.81

2025-03-31

1.16

2024-12-31

1.69

2024-09-30

2.96

2024-06-30

3.41

2024-03-31

4.76

2023-12-31

4.09

2023-09-30

2.39

2023-06-30

2.71

2023-03-31

3.00

2022-12-31

3.25

2022-09-30

7.30

2022-06-30

5.01

2022-03-31

6.00

2021-12-31

4.79

2021-09-30

2.12

2021-06-30

2.34

2021-03-31

3.02

2020-12-31

4.08

2020-09-30

4.07

2020-06-30

0.97

2020-03-31

1.46

2019-12-31

1.85

2019-09-30

1.34

2019-06-30

1.59

2019-03-31

1.71

2018-12-31

1.00

2018-09-30

2.68

2018-06-30

3.94

2018-03-31

3.18

2017-12-31

4.10

2017-09-30

4.74

2017-06-30

2.11

2017-03-31

2.97

2016-12-31

3.68

2016-09-30

3.69

2016-06-30

2.01

2016-03-31

1.28

2015-12-31

2.26

2015-09-30

1.75

2015-06-30

2.79

2015-03-31

3.61

2014-12-31

0.47

2014-09-30

1.55

2014-06-30

3.11

2014-03-31

5.16

2013-12-31

1.25

2013-09-30

0.86

2013-06-30

1.95

2013-03-31

1.49

2012-12-31

2.65

2012-09-30

1.44

2012-06-30

0.49

2012-03-31

1.05

2011-12-31

1.37

2011-09-30

2.14

2011-06-30

2.77

2011-03-31

3.01

2010-12-31

2.76

2010-09-30

6.61

2010-06-30

4.25

2010-03-31

5.12

2009-12-31

5.47

2009-09-30

0.41

2009-06-30

0.48

2009-03-31

0.00

2008-12-31

0.87

2008-09-30

0.00

Quick Ratio (Acid-Test): 1.94

OMER Quick Ratio

OMER Average Quick Ratio (Acid-Test) Chart

OMER Current vs Average Quick Ratio (Acid-Test) Chart

OMER Quick Ratio (Acid-Test) Metrics

OMER Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

OMER Quick Ratio (Acid-Test) History

Related Metrics